Simulations Plus Enters Funded Research Collaboration with Large European Consortium
July 18 2018 - 8:30AM
Business Wire
Enhancements to mechanistic dermal
absorption model in GastroPlus™ will target non-pharmaceutical
markets
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of
modeling and simulation solutions for the pharmaceutical,
biotechnology, chemicals, and consumer goods industries, today
announced that it has entered into a one-year funded research
collaboration with a large European consortium to further develop
and validate the mechanistic Transdermal Compartmental Absorption
and Transit (TCAT™) model in GastroPlus™.
Dr. Viera Lukacova, director of simulation sciences, said: “We
are very pleased to have the opportunity to work with the diverse
membership of this large European consortium to enhance the
GastroPlus TCAT model in support of alternative approaches to
animal testing. The model is already being utilized heavily within
pharmaceutical companies to support transdermal product development
activities. This project will contribute substantially to
improvements in the program, specifically directed toward the
predictions of local exposure within the skin layer following
topical administration of various chemicals. We expect the
developments under this agreement will aid companies and regulatory
agencies as they strive to implement an animal-free chemical safety
assessment program.”
John DiBella, Lancaster division president, added: “The
consortium rigorously evaluated GastroPlus and several other
commercial/academic dermal models on a number of criteria,
including prediction accuracy using blinded data, and the results
presented at the largest toxicology conference in March had
GastroPlus ranked at the top. The outcomes from this collaboration
will be integrated into the next versions of GastroPlus and made
available to clients as an optional add-on module, which should
help us further penetrate into safety research and risk assessment
areas. We look forward to leveraging the experiences, expertise,
and knowledge base of the consortium as we collaborate on the
next-generation dermal absorption modeling platform.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of drug discovery
and development software as well as a leading provider of both
preclinical and clinical pharmacometric consulting services for
regulatory submissions and quantitative systems pharmacology models
for drug-induced liver injury and nonalcoholic fatty liver disease.
The company is a global leader focused on improving the ways
scientists use knowledge and data to predict the properties and
outcomes of pharmaceutical, biotechnology, and chemical agents. Our
software is licensed to and used in the conduct of drug research by
major pharmaceutical, biotechnology, chemical, and consumer goods
companies and regulatory agencies worldwide. Our innovations in
integrating new and existing science in medicinal chemistry,
computational chemistry, pharmaceutical science, biology, and
physiology into our software have made us the leading software
provider for physiologically based pharmacokinetic modeling and
simulation. For more information, visit our website at
www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995 – With the exception of historical
information, the matters discussed in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Words like “believe,” “expect” and “anticipate” mean
that these are our best estimates as of this writing, but that
there can be no assurances that expected or anticipated results or
events will actually take place, so our actual future results could
differ significantly from those statements. Factors that could
cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the
pharmaceutical industry, our ability to finance growth, our ability
to continue to attract and retain highly qualified technical staff,
our ability to identify and close acquisitions on terms favorable
to the Company, and a sustainable market. Further information on
our risk factors is contained in our quarterly and annual reports
and filed with the U.S. Securities and Exchange Commission.
Follow us on Twitter | LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180718005183/en/
Simulations Plus Investor
RelationsMs. Renee Bouche,
661-723-7723renee@simulations-plus.comorHayden IRMr. Cameron Donahue,
651-653-1854cameron@haydenir.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Sep 2023 to Sep 2024